The US pharmaceutical company Moderna has developed a new bivalent vaccine for the new crown, which has been approved by the British authorities, becoming the first country in the world to approve the marketing of a bivalent vaccine for the new crown.
He Bailiang, director of the Center for Infection and Infectious Diseases of the University of Hong Kong, pointed out in a radio program this morning (16th) that the bivalent vaccine has two formulations, one for the original virus and one for Omicron BA.1. According to the data released by the pharmaceutical company in June this year, The effect is obviously better than the currently used monovalent vaccine. In addition, there are currently fewer new crown vaccines available in Hong Kong, and it is believed that the Hong Kong government can consider purchasing.
▼On August 6, infants and young children at Guanyong Vaccination Center will hit Kexing▼
+7
He Bailiang said that the current nucleic acid vaccines are mainly the two major brands Moderna and Pfizer, both of which are similar in safety and efficacy.
For vaccines that integrate various technology platforms, the antibodies produced after nucleic acid vaccination and the validity period are the best.
He pointed out that, unlike the monovalent vaccine currently used in Hong Kong, the formula in the vaccine is only for the original virus. The new crown bivalent vaccine developed by the American pharmaceutical company Moderna, half of the formula is against the original virus, and the other half is against Omicron BA.1 .
The pharmaceutical company has released relevant research data in June this year, which has been reviewed by regulatory agencies around the world. The data reflects the level of antibodies produced after vaccination, and the ability to neutralize the original virus, Omicron BA.1, and Omicron BA.4 and BA.5. are superior to the vaccines currently in use.
There are few vaccine choices in Hong Kong, and there should be advanced deployment
He Bailiang pointed out that the British authorities have approved the use of pharmaceutical factories before mass production, which is an "arrangement of pre-purchase and early deployment", and believes that Hong Kong must consider related issues, "There should be advanced deployment, and it is not good to wait until everyone buys, The contract is signed and the regulatory agency approves it, so you should contact the pharmaceutical factory first.”
He also mentioned that Hong Kong is one of the few places where the vaccine technology platform is relatively simple. There are only inactivated vaccines and nucleic acid vaccines, each of which has only one brand, namely Sinovac and Fubitix vaccines. In contrast, in more than 200 countries in the world, most There are at least 4 or 5 vaccines approved for use by local governments, and at least 3 technology platforms are used.
▼On May 30, citizens rushed to take the third vaccine to cope with the vaccine pass▼
+1
Introducing a third technology platform vaccine to provide options for those who have not been vaccinated due to susceptibility or disease
He suggested that if the government has difficulties in procuring the Fubitai vaccine, it can consider Moderna; at the same time, it should consider purchasing a small amount of a third technology platform, such as a recombinant new coronavirus protein vaccine, so that people who cannot be vaccinated with the existing two vaccines due to sensitivity Some people choose to be vaccinated, "compared to some people to make an extra choice, because of sensitivity and disease reasons, we have to take care of their needs."
▼2.17 Vaccination status of children's community vaccination center in Yuanzhoujiao Gym▼
+2
The U.S. pharmaceutical company Moderna’s new crown vaccine was approved for emergency use by the U.S. Food and Drug Administration in December 2020, and was subsequently approved for emergency use by Canada, the European Union, and the United Kingdom.
As of June this year, U.S. authorities approved the Moderna vaccine for infants over 6 months of age.
As for the new bivalent new crown vaccine mentioned this time, the US pharmaceutical company Moderna disclosed to the media in June this year that it is discussing with the Hong Kong government to formally apply for approval to use this second-generation vaccine in Hong Kong; and the United Kingdom has now approved the use.
Epidemic | The world's first UK approval of Moderna's first bivalent vaccine against Omicron outbreak.
Latest | The number of confirmed cases of hoarseness in children is increasing. The Hospital Authority urges vaccination as soon as possible. Tsing Yi Station and Children's Hospital provide two vaccines starting from 8.15. Side effects are more worried about complications New crown vaccine | 6 months to 3 years old children can be vaccinated, experts say that the BB version of Fubitai is difficult to be vaccinated | He Boliang said that the severe rate of children diagnosed is high. Experts advise not to take antipyretics before injections